Endocrine Abstracts

Recently there has been resurgence in interest in the treatment of iodine negative differentiated thyroid cancer and medullary thyroid cancer with novel agents.

This presentation will review the recent literature on treatment of thyroid cancers with multi-targeted tyrosine kinase inhibitors. Data on the experience of the Royal Marsden Hospital with Sorafenib will be presented. Vascular endothelial growth factor inhibition appears to be a particularly important target for these agents, and future directions of research will be discussed.